1. Home
  2. CNX vs IOVA Comparison

CNX vs IOVA Comparison

Compare CNX & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNX Resources Corporation

CNX

CNX Resources Corporation

HOLD

Current Price

$36.58

Market Cap

5.4B

Sector

Energy

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.54

Market Cap

968.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNX
IOVA
Founded
1860
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
968.6M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
CNX
IOVA
Price
$36.58
$2.54
Analyst Decision
Hold
Buy
Analyst Count
11
12
Target Price
$34.50
$10.45
AVG Volume (30 Days)
2.2M
12.0M
Earning Date
01-29-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.02
N/A
Revenue
$1,930,542,000.00
$250,425,000.00
Revenue This Year
$49.64
$60.71
Revenue Next Year
$2.18
$59.52
P/E Ratio
$18.08
N/A
Revenue Growth
40.99
175.62
52 Week Low
$27.00
$1.64
52 Week High
$42.13
$8.15

Technical Indicators

Market Signals
Indicator
CNX
IOVA
Relative Strength Index (RSI) 43.54 51.51
Support Level $36.36 $2.69
Resistance Level $37.84 $2.89
Average True Range (ATR) 1.06 0.19
MACD -0.33 0.01
Stochastic Oscillator 16.67 50.55

Price Performance

Historical Comparison
CNX
IOVA

About CNX CNX Resources Corporation

CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: